In the previous Keynote 158 trial for the cervical cancer cohort, a phase II trial evaluating pembrolizumab mono therapy in recurrent or metastatic cervical cancer, 83.7% of all patients showed a PD-L1-CPS above one. The gene discussed is CD274; the disease is cervical carcinoma.